Genetic Abnormalities and Biological Changes of Panic Disorder Patients After Pharmacotherapy

Genetic Abnormalities and Changes of Autonomic Nervous System, Serotonin System, and Neuroendocrine System According to Pharmacotherapy in Panic Disorder

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00515996

Enrollment

Registered

2007-08-14

Start date

2006-01-31

Completion date

2008-12-31

Last updated

2007-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Keywords

panic disorder, paroxetine, genetic polymorphism, serotonin

Brief summary

We plan to examine genetic polymorphism of catechol-O-methyltransferase in panic disorder and neurobiological changes of panic disorder patients after 12 weeks of pharmacotherapy with paroxetine. We plan to include 40 panic disorder patients and 40 normal control subjects in this study for 3 years.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Panic disorder

Exclusion criteria

* Other major medical or psychiatric illnesses

Countries

South Korea

Outcome results